LENZ Therapeutics Files 2025 Proxy Statement
Ticker: LENZ · Form: DEF 14A · Filed: Apr 28, 2025 · CIK: 1815776
| Field | Detail |
|---|---|
| Company | Lenz Therapeutics, Inc. (LENZ) |
| Form Type | DEF 14A |
| Filed Date | Apr 28, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, annual-meeting, governance
TL;DR
LENZ proxy filed for June 10 meeting - shareholders vote soon.
AI Summary
LENZ Therapeutics, Inc. filed its definitive proxy statement (DEF 14A) on April 28, 2025, for its annual meeting on June 10, 2025. The company, formerly known as Graphite Bio, Inc. and Integral Medicines, Inc., is in the biological products sector. The filing details information related to the company's governance and shareholder matters.
Why It Matters
This filing provides shareholders with crucial information regarding the company's upcoming annual meeting, including proposals to be voted on, director nominations, and executive compensation, enabling informed participation in corporate governance.
Risk Assessment
Risk Level: low — This is a routine DEF 14A filing for an annual meeting, not indicating immediate financial or operational risks.
Key Numbers
- 20250610 — Annual Meeting Date (Shareholders will vote on proposals at this date.)
- 20250428 — Filing Date (Date the proxy statement was filed with the SEC.)
Key Players & Entities
- LENZ Therapeutics, Inc. (company) — Registrant
- Graphite Bio, Inc. (company) — Former company name
- Integral Medicines, Inc. (company) — Former company name
- 0001193125-25-100630 (filing_id) — Accession Number
- 20250428 (date) — Filing Date
- 20250610 (date) — Meeting Date
FAQ
What is the primary purpose of this DEF 14A filing?
The primary purpose is to provide shareholders with information for the upcoming annual meeting on June 10, 2025, including details on voting matters, director nominations, and executive compensation.
When is the annual meeting of LENZ Therapeutics, Inc. scheduled?
The annual meeting is scheduled for June 10, 2025.
What were some of the previous names of LENZ Therapeutics, Inc.?
LENZ Therapeutics, Inc. was formerly known as Graphite Bio, Inc. and Integral Medicines, Inc.
What is the Standard Industrial Classification (SIC) code for LENZ Therapeutics, Inc.?
The SIC code for LENZ Therapeutics, Inc. is 2836, which corresponds to Biological Products (No Diagnostic Substances).
On what date was this definitive proxy statement filed with the SEC?
This definitive proxy statement was filed with the SEC on April 28, 2025.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 28, 2025 regarding LENZ Therapeutics, Inc. (LENZ).